Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.45 |
| ▸ | LPL | P06858 | 7/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | CA2 | P00918 | 7/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362044 | 0.94 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2034800 | 0.89 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2700792 | 0.89 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL17872784 | 0.89 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2034799 | 0.89 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL15900053 | 0.87 | F11 (0.42) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2033871 | 0.86 | LIPG (0.41) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2033870 | 0.86 | LIPG (0.41) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL9958898 | 0.85 | F11 (0.41) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL9958895 | 0.85 | F11 (0.41) | LIPGLPLP4HBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-4321515-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308238-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-01-04 | — | — | US | disclosed |
| EP-4274569-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-4026832-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Almac Discovery Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| CN-107080747-B | Glucosylceramide synthase inhibitors | 建新公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-2768798-A1 | NOVEL PHENICOL ANTIBACTERIALS | Zoetis LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2516435-B1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LTD (GB) | 2014-08-06 | — | — | EP | disclosed |
| EP-2685986-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8569331-B2 | Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds | ARQULE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2013057619-A1 | NOVEL PHENICOL ANTIBACTERIALS | AH USA 42 LLC (US) | 2013-04-25 | — | — | WO | disclosed |
| EP-2516435-A1 | INHIBITORS OF AKT ACTIVITY | Almac Discovery Limited (GB) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012129084-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | ARQULE, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2011077098-A9 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011077098-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | LIPG 4638/4885LPL 4253/4885P4HB 3255/4885 |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | USP1, USP2, USP3 | LIPG 1510/4885LPL 943/4885P4HB 723/4885 |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | TYMP, DPYD, DHFR | LIPG 4316/4885LPL 3655/4885P4HB 1560/4885 |
| US-20120108574-A1 | Substituted Benzo-Imidazo-Pyrido-Diazepine Compounds | BRD4, BRPF3, BRD3 | LIPG 4586/4885LPL 4587/4885P4HB 3278/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | LIPG 1561/4885LPL 1876/4885P4HB 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.